NHS in talks to roll out Alzheimer’s drug
The pTau217 test can identify Alzheimer’s pathology in 18 minutes and is expected to reach clinicians in six to nine months, researchers said.
- On Thursday, Health Minister Mark Butler will launch the Asia-Pacific Centre of Excellence for Alzheimer's Diagnosis in Sydney, following the Therapeutic Goods Administration's approval of the pTau217 blood test for clinical use.
- Unlike the previously approved pTau181 'rule-out' test, the new pTau217 assay functions as both a 'rule-out' and 'rule-in' test, achieving about 90 per cent diagnostic accuracy.
- Processing samples in 18 minutes, the new diagnostic tool offers a viable alternative to invasive lumbar punctures or expensive PET scans currently used for confirming pathology.
- NeuRA CEO Professor Matthew Kiernan stated the centre will generate reference data required for a Pharmaceutical Benefits Scheme listing, enabling doctors across Australia to order the test within six to nine months.
- Because protein changes occur 30 years before symptoms develop, early detection allows clinicians to intervene with disease-modifying therapies before significant neuronal death occurs in Alzheimer disease.
9 Articles
9 Articles
Sydney Morning Herald
The AgeAlzheimer’s blood test to give Australians invaluable gift of time
While some facilities in Australia are already using the blood test for research, she said this is the first time it will be available clinically, with results delivered in just 18 minutes.
The British health service NHS has started negotiations to provide the first drugs that have been proven to slow the progression of Alzheimer's disease.
Monique Yohanan: Better access to Alzheimer's drugs needed (Opinion)
Nearly 80% of voters — including 78% of independents — support better access to coverage for Alzheimer’s detection and treatment. That’s according to a poll released in May. Furthermore, 89% say coverage restrictions from Medicare and private insurers are blocking…
Mini Brains May Help Choose Better Alzheimer's Treatments
Finding the right medicine for Alzheimer’s disease is often a process of trial and error. Many patients receive drugs to manage depression, anxiety, or agitation, yet the results vary greatly. Scientists have long wanted a way to know in advance which treatment is most likely to help each person. A team from Johns Hopkins Medicine […] The post Mini Brains May Help Choose Better Alzheimer’s Treatments appeared first on Knowridge Science Report.
Game-Changing Alzheimer's Treatments Now Available in Australia
For the first time, Australians can access disease-modifying treatments for Alzheimer’s disease—marking a historic shift in dementia care. The recently approved therapies donanemab and lecanemab represent a major breakthrough. Unlike previous treatments that only managed symptoms like memory loss, these new monoclonal antibody therapies actually slow disease progression by targeting amyloid buildup in the brain. While further research is needed …
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
